NCT04233567 2026-02-24
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
8 trialsNCT02657486 2026-02-09
BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT01928459 2020-12-09
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
Novartis
Phase 1 Completed
NCT01697605 2020-12-08
A Phase I Study of Oral BGJ398 in Asian Patients
Novartis
Phase 1 Completed
NCT02257541 2020-03-30
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01975701 2019-12-04
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Novartis
Phase 2 Completed
NCT01004224 2019-10-04
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Novartis
Phase 1 Completed